Canntab Therapeutics Limited
CTABF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Revenue | $293 | $0 | $133 | $240 |
| % Growth | – | -100% | -44.4% | – |
| Cost of Goods Sold | $1,232 | $263 | $0 | $96 |
| Gross Profit | -$939 | -$263 | $133 | $144 |
| % Margin | -320.1% | – | 100% | 59.8% |
| R&D Expenses | $205 | $80 | $106 | $128 |
| G&A Expenses | $2,601 | $2,576 | $2,144 | $2,437 |
| SG&A Expenses | $2,827 | $2,704 | $2,313 | $2,437 |
| Sales & Mktg Exp. | $226 | $128 | $169 | $0 |
| Other Operating Expenses | $193 | $472 | $331 | $0 |
| Operating Expenses | $3,225 | $3,256 | $2,749 | $2,742 |
| Operating Income | -$4,164 | -$3,519 | -$2,616 | -$2,502 |
| % Margin | -1,419.4% | – | -1,961.8% | -1,042.4% |
| Other Income/Exp. Net | $475 | -$900 | $0 | $43 |
| Pre-Tax Income | -$3,689 | -$4,420 | -$2,607 | -$2,459 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,689 | -$4,420 | -$2,607 | -$2,459 |
| % Margin | -1,257.6% | – | -1,955.4% | -1,024.4% |
| EPS | -0.098 | -0.13 | -0.096 | -0.097 |
| % Growth | 24.8% | -35.4% | 1.2% | – |
| EPS Diluted | -0.098 | -0.13 | -0.096 | -0.097 |
| Weighted Avg Shares Out | 37,724 | 34,553 | 27,169 | 25,299 |
| Weighted Avg Shares Out Dil | 37,724 | 34,553 | 27,169 | 25,299 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $43 |
| Interest Expense | $567 | $189 | $27 | $0 |
| Depreciation & Amortization | $635 | $460 | $296 | $81 |
| EBITDA | -$2,488 | -$3,134 | -$2,285 | -$2,421 |
| % Margin | -848% | – | -1,713.8% | -1,008.8% |